Targeting FLT3 to treat leukemia
Introduction: Approximately 23% of acute myeloid leukemia (AML) patients younger than 60 years of age carry a mutation in the transmembrane domain of the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/internal tandem duplications [ITD]). In normal karyotype AML, the presence of a FLT3/ITD mutation is...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Revisão |
| Hizkuntza: | ingelesa |
| Argitaratua: |
2014
|
| Sarrera elektronikoa: | https://doi.org/10.1517/14728222.2014.960843 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|